Trial shows 3 benefits for JAK inhibitors in RA

Using tofacitinib (Xeljanz) in combination with methotrexate offers three major benefits in patients with active rheumatoid arthritis, results from the ORAL Strategy trial suggest.

The combination of an oral Janus Kinase (JAK) inhibitor had similar efficacy and tolerability to injectable biologics used with methotrexate, according to trial findings published in the Lancet.

Secondly, the onset of action of both therapies appeared to be equally rapid, and thirdly most patients were able to remain on  tofacitinib for 12 months,